📣 VC round data is live. Check it out!

PharmaResearch Valuation Multiples

Discover revenue and EBITDA valuation multiples for PharmaResearch and similar public comparables like Fagron, Granules India, AbCellera, Syngene and more.

PharmaResearch Overview

About PharmaResearch

PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.


Founded

2001

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $396M
EBITDA: $169M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PharmaResearch Financials

PharmaResearch reported last 12-month revenue of $396M and EBITDA of $169M.

In the same LTM period, PharmaResearch generated $305M in gross profit, $169M in EBITDA, and $125M in net income.

Revenue (LTM)


PharmaResearch P&L

In the most recent fiscal year, PharmaResearch reported revenue of $367M and EBITDA of $161M.

PharmaResearch is profitable as of last fiscal year, with gross margin of 74%, EBITDA margin of 44%, and net margin of 31%.

See analyst estimates for PharmaResearch
LTMLast FY202320242025202620272028
Revenue$396M$367M$173M$232M$355M
Gross Profit$305M$272M$126M$166M$272M
Gross Margin77%74%73%72%77%
EBITDA$169M$161M$77M$89M$161M
EBITDA Margin43%44%44%38%45%
EBIT Margin40%40%35%36%40%
Net Profit$125M$115M$51M$61M$109M
Net Margin32%31%29%26%31%

Financial data powered by Morningstar, Inc.

PharmaResearch Stock Performance

PharmaResearch has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


PharmaResearch's stock price is $192.22.

PharmaResearch share price decreased by 1.9% in the last 30 days, and by 42.2% in the last year.

PharmaResearch has an EPS (earnings per share) of $11.03.

See more trading valuation data for PharmaResearch
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-2.8%-1.9%-5.2%-42.2%$11.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PharmaResearch Valuation Multiples

PharmaResearch trades at 4.0x EV/Revenue multiple, and 9.4x EV/EBITDA.

See NTM and 2027E valuation multiples for PharmaResearch

EV / Revenue (LTM)


PharmaResearch Financial Valuation Multiples

As of June 3, 2026, PharmaResearch has market cap of $2B and EV of $2B.

PharmaResearch has a P/E ratio of 15.9x.

LTMLast FY202320242025202620272028
EV/Revenue4.0x4.3x9.2x6.8x4.5x
EV/EBITDA9.4x9.9x20.7x17.9x9.9x
EV/EBIT10.0x10.8x26.0x19.0x11.2x
EV/Gross Profit5.2x5.8x12.6x9.5x5.8x
P/E15.9x17.4x39.4x32.8x18.3x
EV/FCF13.8x15.5x46.3x24.1x16.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PharmaResearch Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PharmaResearch Margins & Growth Rates

PharmaResearch grew revenue by 19% and EBITDA by 16% in the last fiscal year.

In the most recent fiscal year, PharmaResearch reported gross margin of 74%, EBITDA margin of 44%, and net margin of 31%.

See estimated margins and future growth rates for PharmaResearch

PharmaResearch Margins

Last FY202420252026202720282029
Gross Margin74%72%77%77%
EBITDA Margin44%38%45%43%
EBIT Margin40%36%40%40%
Net Margin31%26%31%32%
FCF Margin28%28%27%30%

PharmaResearch Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth19%34%53%23%
Gross Profit Growth24%32%64%24%
EBITDA Growth16%16%81%16%
EBIT Growth20%37%70%24%
Net Profit Growth22%20%79%28%
FCF Growth28%92%48%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

PharmaResearch Operational KPIs

PharmaResearch's Rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaResearch's Rule of X is 100% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PharmaResearch
LTMLast FY202320242025202620272028
Rule of 4062%66%---
Bessemer Rule of X92%100%---
S&M Expenses to Revenue9%15%14%13%16%
G&A Expenses to Revenue-4%4%4%4%
R&D Expenses to Revenue-6%6%6%7%
Opex to Revenue-35%38%36%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PharmaResearch Competitors

PharmaResearch competitors include Fagron, Granules India, AbCellera, Syngene, ST Pharm, Piramal Pharma, Jiuzhou Pharmaceutical, Jubilant Pharmova, PolyPeptide and Anupam Rasayan India.

Most PharmaResearch public comparables operate across Contract Research & Manufacturing, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fagron2.0x1.9x10.1x9.5x
Granules India3.7x3.6x16.6x16.0x
AbCellera20.0x26.5x(8.6x)(7.2x)
Syngene4.5x4.4x17.5x17.3x
ST Pharm7.1x6.5x26.2x24.5x
Piramal Pharma3.0x2.9x26.5x26.3x
Jiuzhou Pharmaceutical1.8x1.8x6.8x6.7x
Jubilant Pharmova2.1x2.1x13.9x13.4x

This data is available for Pro users. Sign up to see all PharmaResearch competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PharmaResearch

When was PharmaResearch founded?PharmaResearch was founded in 2001.
Where is PharmaResearch headquartered?PharmaResearch is headquartered in South Korea.
Is PharmaResearch publicly listed?Yes, PharmaResearch is a public company listed on Korea Exchange.
What is the stock symbol of PharmaResearch?PharmaResearch trades under 214450 ticker.
When did PharmaResearch go public?PharmaResearch went public in 2015.
Who are competitors of PharmaResearch?PharmaResearch main competitors include Fagron, Granules India, AbCellera, Syngene, ST Pharm, Piramal Pharma, Jiuzhou Pharmaceutical, Jubilant Pharmova, PolyPeptide, Anupam Rasayan India.
What is the current market cap of PharmaResearch?PharmaResearch's current market cap is $2B.
What is the current revenue of PharmaResearch?PharmaResearch's last 12 months revenue is $396M.
What is the current revenue growth of PharmaResearch?PharmaResearch revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of PharmaResearch?Current revenue multiple of PharmaResearch is 4.0x.
What is the current EBITDA of PharmaResearch?PharmaResearch's last 12 months EBITDA is $169M.
What is PharmaResearch's EBITDA margin?PharmaResearch's last 12 months EBITDA margin is 43%.
What is the current EV/EBITDA multiple of PharmaResearch?Current EBITDA multiple of PharmaResearch is 9.4x.
What is the current FCF of PharmaResearch?PharmaResearch's last 12 months FCF is $115M.
What is PharmaResearch's FCF margin?PharmaResearch's last 12 months FCF margin is 29%.
What is the current EV/FCF multiple of PharmaResearch?Current FCF multiple of PharmaResearch is 13.8x.
How many companies PharmaResearch has acquired to date?PharmaResearch hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies PharmaResearch has invested to date?PharmaResearch hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to PharmaResearch

Lists including PharmaResearch

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial